PYC is pleased to update shareholders on progress made in the June quarter.
Highlights:
- Successful completion of the proof of concept validation for our intracellular delivery platform across multiple cargo classes and in multiple tissue types both in vitro and in vivo;
- Initiation of screening our newly enriched libraries to identify ‘second generation’ CPPs with:
Improved efficiency of delivery;
Cell type specificity; and
Different properties enabling delivery of different classes of therapeutic cargoes;
- Successful results in the peptide vaccine program and expansion beyond oncology indications.
- Publication of our in-house developed methodology for evaluation of CPPs in vitro in a peer-reviewed journal (Biomolecules)
For further information please download PDF attached:
Download this document
